Technical Analysis for NGNE - Neurogene, Inc.

Grade Last Price % Change Price Change
B 46.07 4.68% 2.06
NGNE closed up 4.68 percent on Friday, November 1, 2024, on 86 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 12
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 4.68%
Hammer Candlestick Bullish 4.68%
Stochastic Buy Signal Bullish 4.68%
Lower Bollinger Band Touch Weakness 4.68%
Oversold Stochastic Weakness 4.68%
Down 3 Days in a Row Weakness 5.33%
Oversold Stochastic Weakness 5.33%
Oversold Stochastic Weakness 2.04%
20 DMA Resistance Bearish 0.30%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 20 hours ago
Up 3% about 23 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Up 2% about 23 hours ago
Hammer Candlestick Entry about 24 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Neurogene, Inc. Description

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and by designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Rare Diseases Gene Therapy Medical Genetics Genetic Engineering Central Nervous System Disorders Gene Delivery Molecular Genetics Neurological Diseases Transgene

Is NGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.205
52 Week Low 12.49
Average Volume 106,783
200-Day Moving Average 37.86
50-Day Moving Average 43.05
20-Day Moving Average 48.90
10-Day Moving Average 47.27
Average True Range 3.07
RSI (14) 49.24
ADX 19.12
+DI 21.98
-DI 22.92
Chandelier Exit (Long, 3 ATRs) 46.01
Chandelier Exit (Short, 3 ATRs) 50.60
Upper Bollinger Bands 54.73
Lower Bollinger Band 43.07
Percent B (%b) 0.26
BandWidth 23.84
MACD Line 0.45
MACD Signal Line 1.52
MACD Histogram -1.0695
Fundamentals Value
Market Cap 590.79 Million
Num Shares 12.8 Million
EPS
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.71
Resistance 3 (R3) 48.47 47.35 48.27
Resistance 2 (R2) 47.35 46.68 47.47 48.12
Resistance 1 (R1) 46.71 46.26 47.03 46.95 47.98
Pivot Point 45.59 45.59 45.75 45.71 45.59
Support 1 (S1) 44.95 44.92 45.27 45.19 44.16
Support 2 (S2) 43.83 44.50 43.95 44.02
Support 3 (S3) 43.19 43.83 43.87
Support 4 (S4) 43.43